2024 ended on a strong note; 2025 outlook surpassed expectations
05/02/25 -"The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the street’s expectations. While we expect ..."
Pages
71
Language
English
Published on
05/02/25
You may also be interested by these reports :
17/03/25
Virbac’s 2024 operating profitability was somewhat ahead of the street’s expectations, backed by favourable prices, higher volumes and an improved ...
12/03/25
Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy ...
11/03/25
Vague outlook and slight miss on topline might offer weakness to further build up a position
05/03/25
Worth building a position ahead of results at current price